₹111.12
−3.50%NSE close, 16 Nov 2026
+14.25%
Aarey Drugs & Pharmaceuticals is a small cap company, listed on NSE under the symbol AAREYDRUGS. At ₹111.12 a share, the market values the whole company at ₹315 crore.
In FY26, it reported sales of ₹472 crore and a net profit of ₹4 crore, an operating margin of 1.5%. Over the last three years, sales grew 4.5% a year and net profit fell 8.4% a year.
The market values the company at 69.7 times its profit over the last twelve months and 1.86 times its book value; its return on equity is 2.7% and its borrowings are 0.33 times its equity.
Promoters hold 41.45% of the shares. Foreign institutions hold 4.27%, and domestic institutions, mutual funds among them, 1.44%.
Over the past year the share price has risen 12.0%, and it is 4.9% below its 52-week high.
₹ crore. Standalone figures: the company files no consolidated results.
The financial results for the period ended September 30, 2026.
A copy Srutinizers report and voting results of Annual General Meeting held on September 30, 2026.
Has informed regarding Disclosure of material issue
Has informed regarding Disclosure of material issue
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 76.5 | 210 | 127 | 105 | 134 | 108 | 102 | 84.2 | 96.4 | 189 | 44.6 | 88.6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 73.8 | 212 | 126 | 101 | 132 | 113 | 101 | 81.5 | 97.9 | 185 | 43.3 | 86.5 |
| Operating profit | 2.7 | −1.4 | 1.2 | 3.7 | 2.2 | −4.9 | 1.7 | 2.6 | −1.5 | 4.3 | 1.3 | 2.1 |
| Operating margin | 3.5% | -0.7% | 0.9% | 3.5% | 1.6% | -4.5% | 1.7% | 3.1% | -1.6% | 2.3% | 3.0% | 2.4% |
| Other income | 0.3 | 5.1 | 1.6 | 0.0 | 0.7 | 7.5 | 1.6 | 0.8 | 4.2 | −0.4 | 1.7 | 1.6 |
| Interest | 1.1 | 1.2 | 1.0 | 1.5 | 0.9 | 2.5 | 1.0 | 1.3 | 0.9 | 1.8 | 1.7 | 1.2 |
| Depreciation | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 | −1.4 | 0.5 | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 |
| Profit before tax | 1.5 | 2.2 | 1.3 | 1.8 | 1.4 | 1.6 | 1.7 | 1.5 | 0.9 | 1.3 | 0.5 | 1.7 |
| Tax | 0.4 | −0.0 | 0.1 | 0.2 | 0.7 | 1.2 | 0.4 | 0.5 | 0.4 | −0.3 | −0.5 | 0.3 |
| Net profit | 1.0 | 2.2 | 1.2 | 1.6 | 0.7 | 0.5 | 1.4 | 1.0 | 0.6 | 1.6 | 1.0 | 1.4 |
| EPS (₹) | 0.40 | 0.77 | 0.88 | 1.14 | 0.26 | 0.04 | 0.48 | 0.72 | 0.20 | 0.55 | 0.36 | 0.43 |
₹ crore, financial years to March.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales | 493 | 414 | 396 | 474 | 472 |
| Expenses | 481 | 411 | 391 | 472 | 465 |
| Operating profit | 11.3 | 3.0 | 4.5 | 2.3 | 7.2 |
| Operating margin | 2.3% | 0.7% | 1.1% | 0.5% | 1.5% |
| Other income | 2.8 | 7.4 | 7.0 | 9.8 | 6.1 |
| Interest | 2.0 | 2.9 | 4.4 | 4.0 | 5.0 |
| Depreciation | 2.0 | 1.6 | 1.7 | 1.9 | 2.9 |
| Profit before tax | 10.0 | 6.5 | 5.4 | 6.1 | 5.4 |
| Tax | 2.5 | 1.3 | 0.7 | 2.1 | 1.5 |
| Net profit | 7.5 | 5.2 | 4.7 | 4.0 | 4.0 |
| EPS (₹) | 2.72 | 1.48 | 1.77 | 3.27 | 1.39 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 18.6 | 9.7 | 10.1 | −14.8 |
| From investing | 24.4 | −5.9 | −12.4 | 0.2 |
| From financing | 4.4 | −3.8 | 2.2 | 14.6 |
| Spent on fixed assets | −2.2 | 0 | −12.4 | −0.2 |
| Free cash flow | 16.4 | 9.7 | −2.3 | −15.1 |
Margins, returns, debt, tax and cash.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Net margin | 1.5% | 1.2% | 1.2% | 0.8% | 0.8% |
| Operating margin | 2.3% | 0.7% | 1.1% | 0.5% | 1.5% |
| Return on equity | – | 4.4% | 3.5% | 2.9% | 2.6% |
| Return on capital employed | – | 6.0% | 5.9% | 5.8% | 5.2% |
| Return on assets | – | 1.8% | 1.5% | 1.7% | 1.3% |
| Debt to equity | – | 0.32 | 0.24 | 0.25 | 0.33 |
| Interest coverage | 6.00 | 3.30 | 2.20 | 2.50 | 2.10 |
| Debt to assets | – | 0.13 | 0.10 | 0.15 | 0.17 |
| Current ratio | – | 1.61 | 0.58 | 2.20 | 1.81 |
| Quick ratio | – | 1.44 | 0.38 | 1.73 | 1.53 |
| Cash ratio | – | 0.00 | 0.01 | 0.02 | 0.01 |
| Asset turnover | – | 1.42 | 1.30 | 1.99 | 1.59 |
| Fixed asset turnover | – | 29.72 | 26.99 | 29.22 | 18.32 |
| Inventory turnover | – | – | 11.00 | 10.20 | 10.90 |
| Receivables turnover | – | 2.20 | – | 3.70 | 3.60 |
| Gross margin | – | – | 3.5% | 2.5% | 3.8% |
| Cash from operations to profit | 247.0% | – | – | 240.0% | 255.0% |
| Effective tax rate | 24.9% | 20.6% | 12.1% | 34.1% | 26.8% |
Has informed regarding Disclosure of material issue
Proceedings of Annual General Meeting held on September 30, 2026
Outcome of Board Meeting held on August 06, 2026.
Outcome of Board Meeting held on September 30, 2026.
The AGM Intimation letter that has been sent to the Shareholders under Regulation 36(1)(b) of the SEBI Listing Regulations, 2015
Notice of Annual General Meeting to be held on September 30, 2026
.Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of Book Closure/ E-Voting period for the 36th Annual General Meeting
Outcome of Board Meeting held on September 05, 2026.
The unaudited financial results for the period ended Jun 30, 2026.
Outcome of Board Meeting held on August 06, 2026.